Bisphosphonates: Mechanism of action and role in clinical practice

Research output: Contribution to journalArticle

595 Citations (Scopus)

Abstract

Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

Original languageEnglish (US)
Pages (from-to)1032-1045
Number of pages14
JournalMayo Clinic Proceedings
Volume83
Issue number9
DOIs
StatePublished - 2008

Fingerprint

Diphosphonates
Osteoclasts
Osteitis Deformans
Bone and Bones
Osteogenesis Imperfecta
Osteonecrosis
Hypercalcemia
Jaw
Multiple Myeloma
PubMed
Bone Density
Osteoporosis
Neoplasms
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bisphosphonates : Mechanism of action and role in clinical practice. / Drake, Matthew M; Clarke, Bart; Khosla, Sundeep.

In: Mayo Clinic Proceedings, Vol. 83, No. 9, 2008, p. 1032-1045.

Research output: Contribution to journalArticle

@article{4e70697fa188407d866c5fed6ebc9f6e,
title = "Bisphosphonates: Mechanism of action and role in clinical practice",
abstract = "Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.",
author = "Drake, {Matthew M} and Bart Clarke and Sundeep Khosla",
year = "2008",
doi = "10.4065/83.9.1032",
language = "English (US)",
volume = "83",
pages = "1032--1045",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Bisphosphonates

T2 - Mechanism of action and role in clinical practice

AU - Drake, Matthew M

AU - Clarke, Bart

AU - Khosla, Sundeep

PY - 2008

Y1 - 2008

N2 - Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

AB - Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.

UR - http://www.scopus.com/inward/record.url?scp=51349163043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51349163043&partnerID=8YFLogxK

U2 - 10.4065/83.9.1032

DO - 10.4065/83.9.1032

M3 - Article

C2 - 18775204

AN - SCOPUS:51349163043

VL - 83

SP - 1032

EP - 1045

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -